Clinical features of patients participating in the study
| . | N . | IS . | Outcome . | No. of expanded Vβ families* . | |
|---|---|---|---|---|---|
| CD4+(28dim) . | CD8+(28dim) . | ||||
| AA | |||||
| sAA | 20 | Yes, n = 15 | R, n = 12 | 3.0 (3.6) | 2.1 (2.1) |
| NR, n = 3 | 1.0 (3.6) | 2.0 (2.3) | |||
| No, n = 5 | NA | 2.0 (3.6) | 2.4 (3.0) | ||
| mAA | 3 | No, n = 3 | NA | 2.6 (2.6) | 2.0 (4.0) |
| PNH | |||||
| Hemolytic | 6 | No, n = 6 | NA | 2.6 (3.0) | 2.8 (2.5) |
| AA/PNH | 4 | No, n = 4 | NA | 2.0 (3.2) | 3.0 (2.5) |
| . | N . | IS . | Outcome . | No. of expanded Vβ families* . | |
|---|---|---|---|---|---|
| CD4+(28dim) . | CD8+(28dim) . | ||||
| AA | |||||
| sAA | 20 | Yes, n = 15 | R, n = 12 | 3.0 (3.6) | 2.1 (2.1) |
| NR, n = 3 | 1.0 (3.6) | 2.0 (2.3) | |||
| No, n = 5 | NA | 2.0 (3.6) | 2.4 (3.0) | ||
| mAA | 3 | No, n = 3 | NA | 2.6 (2.6) | 2.0 (4.0) |
| PNH | |||||
| Hemolytic | 6 | No, n = 6 | NA | 2.6 (3.0) | 2.8 (2.5) |
| AA/PNH | 4 | No, n = 4 | NA | 2.0 (3.2) | 3.0 (2.5) |
For schedules and regimens of immunosuppression, please see “Patients and methods.” Vβ, variable β chain; IS, immunosupression; AA, aplastic anemia; sAA, severe aplastic anemia; mAA, mild aplastic anemia; R, responder; NR, nonresponder; NA, not applicable (patients were not treated or information was not available); PNH, paroxysmal nocturnal hemoglobinuria.
Values represent the average number of pathologically expanded Vβ families found when individual patient groups were analyzed. The number of pathologically expanded Vβ families within the effector cell (CD28dim) pool is shown in parentheses. The definition of a pathologic expansion is given in “Patients and methods.”